PRF Technologies Ltd. (PRFX)
PRF Technologies Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Tel Aviv, TA, IL. The stock last traded at $1.03, down 5.91% on the session, giving a market capitalisation of $83,351. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -33000.0%. Its beta of 1.04 implies it has historically moved more than the broad market.
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
PRF Technologies Ltd. is most often compared with the following Healthcare names: